Table 2.
Demographic, personality and clinical characteristics of the sample
| Measure | Controls | CD | p | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Male (n = 24) | Female (n = 27) | Male (n = 26) | Female (n = 23) | ||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
| Age (years) | 14.79 | 2.18 | 15.51 | 1.94 | 15.76 | 2.15 | 15.60 | 1.72 | ns |
| Estimated IQ | 101.33 | 11.77 | 95.85 | 14.22 | 90.88 | 9.78 | 92.04 | 14.07 | 0.006* (controls > CD) |
| YPI-total | 97.83 | 12.98 | 90.00 | 15.31 | 106.88 | 24.68 | 104.86 | 19.84 | 0.002* (CD > controls) |
| YPI-CU | 22.54 | 3.71 | 18.59 | 3.69 | 25.76 | 5.89 | 19.95 | 4.46 | 0.013* (CD > controls) <0.001** (male > female) |
| CD Symptoms | 0.16 | 0.38 | 0.11 | 0.32 | 4.92 | 3.07 | 3.65 | 2.14 | <0.001* (CD > controls) |
| ADHD Symptoms | 0.04 | 0.20 | 0.22 | 0.69 | 4.69 | 4.73 | 4.08 | 4.02 | <0.001* (CD > controls) |
| Comorbid conditions | N | ||||||||
| Depression | 3 | ||||||||
| Substance abuse | 4 | ||||||||
| Psychoactive medication | N | ||||||||
| Concerta | 2 | ||||||||
| Strattera | 2 | ||||||||
| Venlafaxine | 1 | ||||||||
| CD onset type^ | N | ||||||||
| Childhood onset | 22 | ||||||||
| Adolescence onset | 12 | ||||||||
CD conduct disorder, SD standard deviation, IQ intelligence quotient, YPI-total total score on the Youth Psychopathic traits Inventory, YPI-CU callous-unemotional scale score on the Youth Psychopathic traits Inventory, CD symptoms number of conduct disorder symptoms from the K-SADS-PL, ADHD attention-deficit/hyperactivity disorder, ns no significant effects
* Significant effect of Group
** Significant effect of Sex
^Age-of-onset data were unavailable for 15 subjects